From the National Heart and Lung Institute (G.R., E.S.) and the Department of Infectious Disease (C.C.), Imperial College London; the U.K. Vaccines Taskforce (A.G.); and hVIVO Services (A.C.) - all in London; and the Department of Paediatrics, University of Oxford, Oxford, United Kingdom (H.M.).
Humans, Antiviral Agents, Human Experimentation, Clinical Trials as Topic, COVID-19, SARS-CoV-2, COVID-19 Vaccines